Viracta Therapeutics
2533 S. Coast Hwy 101
Suite 210
Cardiff
California
92007
United States
Website: http://www.viracta.com/
104 articles about Viracta Therapeutics
-
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/7/2024
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial results for the fourth quarter and full-year of 2023 and provided a business update.
-
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
2/29/2024
Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced that its lead development program, Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, has completed Stage 2 enrollment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort of the NAVAL-1 trial.
-
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/6/2024
Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced that Mark Rothera, its President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 9:00 a.m. PT/12:00 p.m. ET.
-
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
1/4/2024
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a clinical update, including its roadmap for advancing Nana-val’s clinical development in 2024.
-
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
12/12/2023
Viracta Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation to Nana-val (nanatinostat in combination with valganciclovir).
-
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
12/4/2023
Viracta Therapeutics, Inc. today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcinoma (NPC) showed two ongoing confirmed partial responses (PRs) at higher dose levels.
-
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/9/2023
Viracta Therapeutics today provided a business update and reported financial results for the third quarter of 2023.
-
Viracta Therapeutics to Present at Upcoming November 2023 Investor Conferences
11/7/2023
Viracta Therapeutics, Inc., a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that Company’s Management will participate in upcoming investor conferences in November.
-
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
10/4/2023
Viracta Therapeutics, Inc. today announced that it plans to highlight new preliminary clinical and preclinical data from studies of nanatinostat and valganciclovir (Nana-val), its all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, during an R&D Day today, Wednesday, October 4, 2023, at 8:00 a.m. EDT.
-
Viracta Therapeutics to Host R&D Day on October 4, 2023
9/5/2023
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that it will host a Research and Development (R&D) Day on Wednesday, October 4, 2023, focused on Nana-val, its all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers.
-
Viracta Therapeutics Announces New Employment Inducement Grant - August 18, 2023
8/18/2023
Viracta Therapeutics, Inc. announced that, in connection with the appointment of Darrel P. Cohen, M.D., Ph.D. as Viracta’s new Chief Medical Officer, the Compensation Committee of Viracta’s Board of Directors granted Dr. Cohen a non-qualified stock option to purchase 235,000 shares of common stock under Viracta’s 2021 Inducement Equity Incentive Plan.
-
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8/14/2023
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the second quarter of 2023.
-
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
8/8/2023
Viracta Therapeutics, Inc. today announced the publication of clinical data from an open-label, multicenter, Phase 1b/2 study of Nana-val in 55 patients with R/R EBV+ lymphoma in Blood Advances.
-
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
8/7/2023
Viracta Therapeutics, Inc. today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical
-
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
6/28/2023
Viracta Therapeutics, Inc. today announced that the relapsed or refractory EBV + peripheral T-cell lymphoma (R/R EBV + PTCL) cohort of its pivotal NAVAL-1 clinical trial has met the pre-specified efficacy threshold for expansion into Stage 2 of the study.
-
Viracta Therapeutics to Present at the 2023 Jefferies Healthcare Conference
5/31/2023
Viracta Therapeutics, Inc. announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:00 p.m. EDT.
-
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
5/11/2023
Viracta Therapeutics, Inc. announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT.
-
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
5/8/2023
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced financial results for the first quarter of 2023 and recent clinical program updates.
-
Viracta Therapeutics Announces Departure of Chief Medical Officer
5/2/2023
Viracta Therapeutics, Inc., a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5, 2023.
-
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
4/19/2023
Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.